We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Industry Feedback: FDA’s DCT Guidance Lacks Depth on Oversight, Task Log
Industry Feedback: FDA’s DCT Guidance Lacks Depth on Oversight, Task Log
Comments from numerous stakeholders have sounded the alarm over the lack of detail on oversight/responsibility for remote vendors and a new“task log” in the FDA’s draft guidance on decentralized trials (DCT).